Roquefort Therapeutics Management
Management criteria checks 1/4
Roquefort Therapeutics' CEO is Ajan Reginald, appointed in Sep 2022, has a tenure of 1.67 years. total yearly compensation is £305.80K, comprised of 90.9% salary and 9.1% bonuses, including company stock and options. directly owns 9.03% of the company’s shares, worth £530.67K. The average tenure of the management team and the board of directors is 1.7 years and 1.9 years respectively.
Key information
Ajan Reginald
Chief executive officer
UK£305.8k
Total compensation
| CEO salary percentage | 90.9% |
| CEO tenure | 1.7yrs |
| CEO ownership | 9.0% |
| Management average tenure | 1.7yrs |
| Board average tenure | 1.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | UK£306k | UK£278k | -UK£2m |
| Sep 30 2023 | n/a | n/a | -UK£2m |
| Jun 30 2023 | n/a | n/a | -UK£2m |
| Mar 31 2023 | n/a | n/a | -UK£2m |
| Dec 31 2022 | UK£284k | UK£81k | -UK£2m |
Compensation vs Market: Ajan's total compensation ($USD382.95K) is about average for companies of similar size in the UK market ($USD347.41K).
Compensation vs Earnings: Ajan's compensation has increased whilst the company is unprofitable.
CEO
Ajan Reginald (51 yo)
1.7yrs
Tenure
UK£305,800
Compensation
Mr. Trevor Ajanthan Reginald, also known as Ajan, is Co-Founder, Chief Executive Officer and Executive Director of Celixir Limited. He serves as CEO & Executive Director at Roquefort Therapeutics plc since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 3.8yrs | UK£152.90k | 4.35% £ 255.6k | |
| CEO & Executive Director | 1.7yrs | UK£305.80k | 9.03% £ 530.7k | |
| Group Chief Scientific Officer & Executive Director | 1.7yrs | UK£100.00k | 0.28% £ 16.2k | |
| Head of Pre-Clinical Research | 1.3yrs | no data | no data |
1.7yrs
Average Tenure
51yo
Average Age
Experienced Management: ROQ's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 3.8yrs | UK£152.90k | 4.35% £ 255.6k | |
| CEO & Executive Director | 1.7yrs | UK£305.80k | 9.03% £ 530.7k | |
| Group Chief Scientific Officer & Executive Director | 1.7yrs | UK£100.00k | 0.28% £ 16.2k | |
| Independent Non-Executive Director | 3.2yrs | UK£24.00k | no data | |
| Non-Executive Director | 2.1yrs | UK£26.81k | no data | |
| Member of Scientific Advisory Board & Advisor to the Board | 2.3yrs | no data | no data | |
| Independent Chief Medical Officer & Member of Scientific Advisory Board | 1.2yrs | no data | no data | |
| Non-Executive Director | 1.7yrs | UK£24.00k | 1.16% £ 68.1k | |
| Member of Scientific Advisory Board | 1.2yrs | no data | no data | |
| Non-Executive Director | 2.1yrs | UK£26.81k | 0.075% £ 4.4k |
1.9yrs
Average Tenure
58yo
Average Age
Experienced Board: ROQ's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.